{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T11:21:36Z","timestamp":1764415296684,"version":"3.46.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Fundac\u0327a\u0303o para a Cie\u0302ncia e a Tecnologia, I.P.","award":["UIDP\/04378\/2020, UIDB\/04378\/2020, LA\/P\/0140\/2020, UI\/BD\/151313\/2021","UIDP\/04378\/2020, UIDB\/04378\/2020, LA\/P\/0140\/2020, UI\/BD\/151313\/2021","UIDP\/04378\/2020, UIDB\/04378\/2020, LA\/P\/0140\/2020, UI\/BD\/151313\/2021"],"award-info":[{"award-number":["UIDP\/04378\/2020, UIDB\/04378\/2020, LA\/P\/0140\/2020, UI\/BD\/151313\/2021","UIDP\/04378\/2020, UIDB\/04378\/2020, LA\/P\/0140\/2020, UI\/BD\/151313\/2021","UIDP\/04378\/2020, UIDB\/04378\/2020, LA\/P\/0140\/2020, UI\/BD\/151313\/2021"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Metabolomics"],"DOI":"10.1007\/s11306-025-02342-z","type":"journal-article","created":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T15:45:12Z","timestamp":1760629512000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Paclitaxel resistance-associated metabolic events in ovarian cancer cells"],"prefix":"10.1007","volume":"21","author":[{"given":"Filipa","family":"Amaro","sequence":"first","affiliation":[]},{"given":"Mariana","family":"Nunes","sequence":"additional","affiliation":[]},{"given":"Paula","family":"Guedes de Pinho","sequence":"additional","affiliation":[]},{"given":"Sara","family":"Ricardo","sequence":"additional","affiliation":[]},{"given":"Joana","family":"Pinto","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2025,10,16]]},"reference":[{"key":"2342_CR1","doi-asserted-by":"publisher","first-page":"122166","DOI":"10.1016\/j.lfs.2023.122166","volume":"333","author":"P Alarcon-Zapata","year":"2023","unstructured":"Alarcon-Zapata, P., Perez, A. J., Toledo-Onate, K., Contreras, H., Ormazabal, V., Nova-Lamperti, E., Aguayo, C. A., Salomon, C., & Zuniga, F. A. (2023). Metabolomics profiling and chemoresistance mechanisms in ovarian cancer cell lines: Implications for targeting glutathione pathway. Life Sciences, 333, 122166. https:\/\/doi.org\/10.1016\/j.lfs.2023.122166","journal-title":"Life Sciences"},{"key":"2342_CR2","doi-asserted-by":"publisher","unstructured":"Amaro, F., Carvalho, M., Bastos, M. L., Guedes de Pinho, P., & Pinto, J. (2024). Metabolomics reveals tyrosine kinase inhibitor Resistance-Associated metabolic events in human metastatic renal cancer cells. International Journal of Molecular Sciences, 25(12), 6328. https:\/\/doi.org\/10.3390\/ijms25126328","DOI":"10.3390\/ijms25126328"},{"key":"2342_CR3","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.molimm.2008.08.266","volume":"46","author":"SP Bak","year":"2008","unstructured":"Bak, S. P., Alonso, A., Turk, M. J., & Berwin, B. (2008). Murine ovarian cancer vascular leukocytes require arginase-1 activity for T cell suppression. Molecular Immunology, 46(2), 258\u2013268. https:\/\/doi.org\/10.1016\/j.molimm.2008.08.266","journal-title":"Molecular Immunology"},{"key":"2342_CR4","doi-asserted-by":"publisher","first-page":"384","DOI":"10.37349\/etat.2024.00224","volume":"5","author":"F Ben Ali","year":"2024","unstructured":"Ben Ali, F., Qmichou, Z., Oukabli, M., Dakka, N., Bakri, Y., Eddouks, M., El, A., & Hassani, R. (2024). Alteration of glucose metabolism and expression of glucose transporters in ovarian cancer. Exploration of Targeted Anti-tumor Therapy, 5, 384\u2013399. https:\/\/doi.org\/10.37349\/etat.2024.00224","journal-title":"Explor Target Antitumor Ther"},{"key":"2342_CR5","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/j.ijnurstu.2012.01.015","volume":"49","author":"L Berben","year":"2012","unstructured":"Berben, L., Sereika, S. M., & Engberg, S. (2012). Effect size estimation: Methods and examples. International Journal of Nursing Studies, 49(8), 1039\u20131047. https:\/\/doi.org\/10.1016\/j.ijnurstu.2012.01.015","journal-title":"IJNS"},{"key":"2342_CR6","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.biocel.2018.12.016","volume":"107","author":"A Bishnu","year":"2019","unstructured":"Bishnu, A., Sakpal, A., Ghosh, N., Choudhury, P., Chaudhury, K., & Ray, P. (2019). Long term treatment of Metformin impedes development of chemoresistance by regulating cancer stem cell differentiation through taurine generation in ovarian cancer cells. International Journal of Biochemistry & Cell Biology, 107, 116\u2013127. https:\/\/doi.org\/10.1016\/j.biocel.2018.12.016","journal-title":"International Journal of Biochemistry & Cell Biology"},{"key":"2342_CR7","doi-asserted-by":"publisher","unstructured":"Bizzarri, M., Dinicola, S., Bevilacqua, A., & Cucina, A. (2016). Broad Spectrum Anticancer Activity of Myo-Inositol and Inositol Hexakisphosphate. International Journal of Endocrinology, 2016, 5616807. https:\/\/doi.org\/10.1155\/2016\/5616807","DOI":"10.1155\/2016\/5616807"},{"key":"2342_CR8","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1056\/NEJMra041842","volume":"351","author":"SA Cannistra","year":"2004","unstructured":"Cannistra, S. A. (2004). Cancer of the ovary. New England Journal of Medicine, 351, 2519\u20132529. https:\/\/doi.org\/10.1056\/NEJMra041842","journal-title":"New England Journal of Medicine"},{"key":"2342_CR9","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.3390\/nu16121816","volume":"16","author":"D Centeno","year":"2024","unstructured":"Centeno, D., Farsinejad, S., Kochetkova, E., Volpari, T., Gladych-Macioszek, A., Klupczynska-Gabryszak, A., Polotaye, T., Greenberg, M., Kung, D., Hyde, E., Alshehri, S., Pavlovic, T., Sullivan, W., Plewa, S., Vakifahmetoglu-Norberg, H., Monsma, F. J., Muller, P. A. J., Matysiak, J., Zaborowski, M., DiFeo, A., Norberg, E., Martin, L. A., & Iwanicki, M. (2024). Modeling of intracellular taurine levels associated with ovarian cancer reveals activation of p53, ERK, mTOR and DNA-damage-sensing-dependent cell protection. Nutrients, 16(12), 1816. https:\/\/doi.org\/10.3390\/nu16121816","journal-title":"Nutrients"},{"key":"2342_CR12","doi-asserted-by":"publisher","unstructured":"Chen, X., Chen, S., & Yu, D. (2020). Metabolic reprogramming of chemoresistant cancer cells and the potential significance of metabolic regulation in the reversal of cancer chemoresistance. Metabolites, 10(7), 289. https:\/\/doi.org\/10.3390\/metabo10070289","DOI":"10.3390\/metabo10070289"},{"key":"2342_CR11","doi-asserted-by":"publisher","first-page":"114711","DOI":"10.1016\/j.jpba.2022.114711","volume":"214","author":"W Chen","year":"2022","unstructured":"Chen, W., Li, Q., Hou, R., Liang, H., Zhang, Y., & Yang, Y. (2022). An integrated metabonomics study to reveal the inhibitory effect and metabolism regulation of taurine on breast cancer. Journal of Pharmaceutical and Biomedical Analysis, 214, 114711. https:\/\/doi.org\/10.1016\/j.jpba.2022.114711","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"2342_CR10","doi-asserted-by":"publisher","first-page":"114442","DOI":"10.1016\/j.biopha.2023.114442","volume":"161","author":"Q Chen","year":"2023","unstructured":"Chen, Q., Shen, L., & Li, S. (2023). Emerging role of inositol monophosphatase in cancer. Biomedicine & Pharmacotherapy, 161, 114442. https:\/\/doi.org\/10.1016\/j.biopha.2023.114442","journal-title":"Biomedicine & Pharmacotherapy"},{"key":"2342_CR13","doi-asserted-by":"publisher","first-page":"3000","DOI":"10.1038\/s41467-019-10979-3","volume":"10","author":"M Czystowska-Kuzmicz","year":"2019","unstructured":"Czystowska-Kuzmicz, M., Sosnowska, A., Nowis, D., Ramji, K., Szajnik, M., Chlebowska-Tuz, J., Wolinska, E., Gaj, P., Grazul, M., Pilch, Z., Zerrouqi, A., Graczyk-Jarzynka, A., Soroczynska, K., Cierniak, S., Koktysz, R., Elishaev, E., Gruca, S., Stefanowicz, A., Blaszczyk, R., Borek, B., Gzik, A., Whiteside, T., & Golab, J. (2019). Small extracellular vesicles containing arginase-1 suppress T-cell responses and promote tumor growth in ovarian carcinoma. Nature Communications, 10, 3000. https:\/\/doi.org\/10.1038\/s41467-019-10979-3","journal-title":"Nature Communications"},{"key":"2342_CR14","doi-asserted-by":"publisher","first-page":"8760","DOI":"10.1038\/s41598-017-09206-0","volume":"7","author":"S Dar","year":"2017","unstructured":"Dar, S., Chhina, J., Mert, I., Chitale, D., Buekers, T., Kaur, H., Giri, S., Munkarah, A., & Rattan, R. (2017). Bioenergetic adaptations in chemoresistant ovarian cancer cells. Scientific Reports, 7, 8760. https:\/\/doi.org\/10.1038\/s41598-017-09206-0","journal-title":"Scientific Reports"},{"key":"2342_CR15","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s00216-010-4425-x","volume":"399","author":"K Dettmer","year":"2011","unstructured":"Dettmer, K., Nurnberger, N., Kaspar, H., Gruber, M. A., Almstetter, M. F., & Oefner, P. J. (2011). Metabolite extraction from adherently growing mammalian cells for metabolomics studies: Optimization of harvesting and extraction protocols. Analytical and Bioanalytical Chemistry, 399, 1127\u20131139. https:\/\/doi.org\/10.1007\/s00216-010-4425-x","journal-title":"Analytical and Bioanalytical Chemistry"},{"key":"2342_CR16","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1002\/cncr.24149","volume":"115","author":"A du Bois","year":"2009","unstructured":"du Bois, A., Reuss, A., Pujade-Lauraine, E., Harter, P., Ray-Coquard, I., & Pfisterer, J. (2009). Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: By the arbeitsgemeinschaft gynaekologische onkologie studiengruppe ovarialkarzinom (AGO-OVAR) and the groupe d\u2019investigateurs Nationaux pour les etudes des cancers de l\u2019ovaire. Cancer, 115(6), 1234\u20131244. https:\/\/doi.org\/10.1002\/cncr.24149","journal-title":"Cancer"},{"key":"2342_CR17","doi-asserted-by":"publisher","first-page":"114092","DOI":"10.1016\/j.bcp.2020.114092","volume":"178","author":"Q Feng","year":"2020","unstructured":"Feng, Q., Li, X., Sun, W., Sun, M., Li, Z., Sheng, H., Xie, F., Zhang, S., & Shan, C. (2020). Targeting G6PD reverses Paclitaxel resistance in ovarian cancer by suppressing GSTP1. Biochemical Pharmacology, 178, 114092. https:\/\/doi.org\/10.1016\/j.bcp.2020.114092","journal-title":"Biochemical Pharmacology"},{"key":"2342_CR18","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1002\/ijc.33588","volume":"149","author":"J Ferlay","year":"2021","unstructured":"Ferlay, J., Colombet, M., Soerjomataram, I., Parkin, D. M., Pineros, M., Znaor, A., & Bray, F. (2021). Cancer statistics for the year 2020: An overview. International Journal of Cancer, 149, 778\u2013789. https:\/\/doi.org\/10.1002\/ijc.33588","journal-title":"International Journal of Cancer"},{"key":"2342_CR19","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.cell.2016.09.031","volume":"167","author":"R Geiger","year":"2016","unstructured":"Geiger, R., Rieckmann, J. C., Wolf, T., Basso, C., Feng, Y., Fuhrer, T., Kogadeeva, M., Picotti, P., Meissner, F., Mann, M., Zamboni, N., Sallusto, F., & Lanzavecchia, A. (2016). L-Arginine modulates T cell metabolism and enhances survival and Anti-tumor activity. Cell, 167(3), 829\u2013842e13. https:\/\/doi.org\/10.1016\/j.cell.2016.09.031","journal-title":"Cell"},{"key":"2342_CR20","doi-asserted-by":"publisher","first-page":"12512","DOI":"10.1039\/D2DT02068H","volume":"51","author":"V Ghini","year":"2022","unstructured":"Ghini, V., Magherini, F., Massai, L., Messori, L., & Turano, P. (2022). Comparative NMR metabolomics of the responses of A2780 human ovarian cancer cells to clinically established Pt-based drugs. Dalton Transactions, 51, 12512\u201312523. https:\/\/doi.org\/10.1039\/D2DT02068H","journal-title":"Dalton Transactions"},{"key":"2342_CR21","doi-asserted-by":"publisher","unstructured":"Ghini, V., Sorbi, F., Fambrini, M., & Magherini, F. (2024). NMR metabolomics of primary ovarian cancer cells in comparison to established Cisplatin-Resistant and -Sensitive cell lines. Cells, 13(8), 661. https:\/\/doi.org\/10.3390\/cells13080661","DOI":"10.3390\/cells13080661"},{"key":"2342_CR22","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.annonc.2023.07.011","volume":"34","author":"A Gonzalez-Martin","year":"2023","unstructured":"Gonzalez-Martin, A., Harter, P., Leary, A., Lorusso, D., Miller, R. E., Pothuri, B., Ray-Coquard, I., Tan, D. S. P., Bellet, E., Oaknin, A., & Ledermann, J. A. (2023). Newly diagnosed and relapsed epithelial ovarian cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Annals of Oncology, 34(10), 833\u2013848. https:\/\/doi.org\/10.1016\/j.annonc.2023.07.011","journal-title":"Annals of Oncology"},{"key":"2342_CR23","doi-asserted-by":"publisher","first-page":"4421","DOI":"10.1007\/s00018-017-2582-1","volume":"74","author":"S Hayton","year":"2017","unstructured":"Hayton, S., Maker, G. L., Mullaney, I., & Trengove, R. D. (2017). Experimental design and reporting standards for metabolomics studies of mammalian cell lines. Cellular and Molecular Life Sciences, 74, 4421\u20134441. https:\/\/doi.org\/10.1007\/s00018-017-2582-1","journal-title":"Cellular and Molecular Life Sciences"},{"key":"2342_CR100","doi-asserted-by":"publisher","unstructured":"International Collaborative Ovarian Neoplasm Group. (2002). Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet, 360(9332), 505\u2013515. https:\/\/doi.org\/10.1016\/S0140-6736(02)09738-6","DOI":"10.1016\/S0140-6736(02)09738-6"},{"key":"2342_CR25","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa, M., & Goto, S. (2000). KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Research, 28(1), 27\u201330. https:\/\/doi.org\/10.1093\/nar\/28.1.27","journal-title":"Nucleic Acids Research"},{"key":"2342_CR26","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1093\/carcin\/bgac019","volume":"43","author":"F Kassie","year":"2022","unstructured":"Kassie, F., Bagherpoor, A. J., Kovacs, K., & Seelig, D. (2022). Combinatory lung tumor Inhibition by myo-inositol and iloprost\/rapamycin: Association with Immunomodulation. Carcinogenesis, 43(6), 547\u2013556. https:\/\/doi.org\/10.1093\/carcin\/bgac019","journal-title":"Carcinogenesis"},{"key":"2342_CR27","doi-asserted-by":"publisher","unstructured":"Kennedy, L., Sandhu, J. K., Harper, M. E., & Cuperlovic-Culf, M. (2020). Role of glutathione in cancer: From mechanisms to therapies. Biomolecules, 10(10), 1429. https:\/\/doi.org\/10.3390\/biom10101429","DOI":"10.3390\/biom10101429"},{"key":"2342_CR28","first-page":"43","volume":"56","author":"J Kigawa","year":"2013","unstructured":"Kigawa, J. (2013). New strategy for overcoming resistance to chemotherapy of ovarian cancer. Yonago Acta Medica, 56, 43\u201350.","journal-title":"Yonago Acta Med"},{"key":"2342_CR30","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/978-1-4614-6093-0_19","volume":"776","author":"T Kim","year":"2013","unstructured":"Kim, T., & Kim, A. K. (2013). Taurine enhances anticancer activity of cisplatin in human cervical cancer cells. Advances in Experimental Medicine and Biology, 776, 189\u2013198. https:\/\/doi.org\/10.1007\/978-1-4614-6093-0_19","journal-title":"Advances in Experimental Medicine and Biology"},{"key":"2342_CR29","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1756-9966-31-14","volume":"31","author":"A Kim","year":"2012","unstructured":"Kim, A., Ueda, Y., Naka, T., & Enomoto, T. (2012). Therapeutic strategies in epithelial ovarian cancer. Journal of Experimental & Clinical Cancer Research, 31, 14. https:\/\/doi.org\/10.1186\/1756-9966-31-14","journal-title":"Journal of Experimental & Clinical Cancer Research : Cr"},{"key":"2342_CR31","doi-asserted-by":"publisher","first-page":"vi24","DOI":"10.1093\/annonc\/mdt333","volume":"24","author":"JA Ledermann","year":"2013","unstructured":"Ledermann, J. A., Raja, F. A., Fotopoulou, C., Gonzalez-Martin, A., Colombo, N., Sessa, C., & Group, E. G. W. (2013). Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 24(6), vi24\u201332. https:\/\/doi.org\/10.1093\/annonc\/mdt333","journal-title":"Annals of Oncology"},{"key":"2342_CR32","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.2353\/ajpath.2010.100105","volume":"177","author":"E Lengyel","year":"2010","unstructured":"Lengyel, E. (2010). Ovarian cancer development and metastasis. American Journal of Pathology, 177(3), 1053\u20131064. https:\/\/doi.org\/10.2353\/ajpath.2010.100105","journal-title":"American Journal of Pathology"},{"key":"2342_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jare.2024.09.005","author":"TL Liang","year":"2024","unstructured":"Liang, T. L., Pan, H. D., Yan, P. Y., Mi, J. N., Liu, X. C., Bao, W. Q., Lian, L. R., Zhang, C. F., Chen, Y., Wang, J. R., Xie, Y., Zhou, H., Yao, X. J., Graham, P., Leung, E. L., Liu, L., & Li, R. Z. (2024). Serum taurine affects lung cancer progression by regulating tumor immune escape mediated by the immune microenvironment. Journal of Advanced Research, 73, 427\u2013442. https:\/\/doi.org\/10.1016\/j.jare.2024.09.005","journal-title":"Journal of Advanced Research"},{"key":"2342_CR34","doi-asserted-by":"publisher","unstructured":"Liebeke, M., & Puskas, E. (2019). Drying enhances signal intensities for global GC-MS metabolomics. Metabolites, 9(4), 68. https:\/\/doi.org\/10.3390\/metabo9040068","DOI":"10.3390\/metabo9040068"},{"key":"2342_CR35","doi-asserted-by":"publisher","unstructured":"Lima, A. R., Araujo, A. M., Pinto, J., Jeronimo, C., Henrique, R., Bastos, M. L., Carvalho, M., & Guedes de Pinho, P. (2018). GC-MS-Based endometabolome analysis differentiates prostate cancer from normal prostate cells. Metabolites, 8(1), 23. https:\/\/doi.org\/10.3390\/metabo8010023","DOI":"10.3390\/metabo8010023"},{"key":"2342_CR36","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s11306-020-01691-1","volume":"16","author":"AR Lima","year":"2020","unstructured":"Lima, A. R., Pinto, J., Barros-Silva, D., Jeronimo, C., Henrique, R., Bastos, M. L., Carvalho, M., & Guedes de Pinho, P. (2020). New findings on urinary prostate cancer metabolome through combined GC-MS and (1)H NMR analytical platforms. Metabolomics, 16, 70. https:\/\/doi.org\/10.1007\/s11306-020-01691-1","journal-title":"Metabolomics"},{"key":"2342_CR37","doi-asserted-by":"publisher","first-page":"44541","DOI":"10.1038\/srep44541","volume":"7","author":"V Lopes-Rodrigues","year":"2017","unstructured":"Lopes-Rodrigues, V., Di Luca, A., Mleczko, J., Meleady, P., Henry, M., Pesic, M., Cabrera, D., van Liempd, S., Lima, R. T., O\u2019Connor, R., Falcon-Perez, J. M., & Vasconcelos, M. H. (2017). Identification of the metabolic alterations associated with the multidrug resistant phenotype in cancer and their intercellular transfer mediated by extracellular vesicles. Scientific Reports, 7, 44541. https:\/\/doi.org\/10.1038\/srep44541","journal-title":"Scientific Reports"},{"key":"2342_CR38","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/978-3-030-93337-1_11","volume":"1370","author":"N Ma","year":"2022","unstructured":"Ma, N., He, F., Kawanokuchi, J., Wang, G., & Yamashita, T. (2022). Taurine and its anticancer functions: in vivo and in vitro study. Advances in Experimental Medicine and Biology, 1370, 121\u2013128. https:\/\/doi.org\/10.1007\/978-3-030-93337-1_11","journal-title":"Advances in Experimental Medicine and Biology"},{"key":"2342_CR39","doi-asserted-by":"publisher","unstructured":"Nayak, A. P., Kapur, A., Barroilhet, L., & Patankar, M. S. (2018). Oxidative phosphorylation: A target for novel therapeutic strategies against ovarian cancer. Cancers, 10(9), 337. https:\/\/doi.org\/10.3390\/cancers10090337","DOI":"10.3390\/cancers10090337"},{"key":"2342_CR24","doi-asserted-by":"publisher","unstructured":"Neoplasm, I. C. O., G (2002). Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: The ICON3 randomised trial. Lancet, 360. https:\/\/doi.org\/10.1016\/S0140-6736(02)09738-6. 505\u2009\u2013\u200915.","DOI":"10.1016\/S0140-6736(02)09738-6"},{"key":"2342_CR40","doi-asserted-by":"publisher","first-page":"112840","DOI":"10.1016\/j.biopha.2022.112840","volume":"149","author":"F Niu","year":"2022","unstructured":"Niu, F., Yu, Y., Li, Z., Ren, Y., Li, Z., Ye, Q., Liu, P., Ji, C., Qian, L., & Xiong, Y. (2022). Arginase: An emerging and promising therapeutic target for cancer treatment. Biomedicine & Pharmacotherapy, 149, 112840. https:\/\/doi.org\/10.1016\/j.biopha.2022.112840","journal-title":"Biomedicine & Pharmacotherapy"},{"key":"2342_CR42","doi-asserted-by":"publisher","unstructured":"Nunes, S. C., & Serpa, J. (2018). Glutathione in ovarian cancer: A Double-Edged sword. International Journal of Molecular Sciences, 19(7), 1882. https:\/\/doi.org\/10.3390\/ijms19071882","DOI":"10.3390\/ijms19071882"},{"key":"2342_CR41","doi-asserted-by":"publisher","first-page":"752127","DOI":"10.3389\/fonc.2021.752127","volume":"11","author":"M Nunes","year":"2021","unstructured":"Nunes, M., Silva, P. M. A., Coelho, R., Pinto, C., Resende, A., Bousbaa, H., Almeida, G. M., & Ricardo, S. (2021). Generation of two Paclitaxel-Resistant High-Grade serous carcinoma cell lines with increased expression of P-Glycoprotein. Frontiers in Oncology, 11, 752127. https:\/\/doi.org\/10.3389\/fonc.2021.752127","journal-title":"Frontiers in Oncology"},{"key":"2342_CR43","doi-asserted-by":"publisher","unstructured":"Ohshima, K., & Morii, E. (2021). Metabolic reprogramming of cancer cells during tumor progression and metastasis. Metabolites, 11(1), 28. https:\/\/doi.org\/10.3390\/metabo11010028","DOI":"10.3390\/metabo11010028"},{"key":"2342_CR44","doi-asserted-by":"publisher","first-page":"151978","DOI":"10.1016\/j.acthis.2022.151978","volume":"125","author":"M Okano","year":"2023","unstructured":"Okano, M., He, F., Ma, N., Kobayashi, H., Oikawa, S., Nishimura, K., Tawara, I., & Murata, M. (2023). Taurine induces upregulation of p53 and Beclin1 and has antitumor effect in human nasopharyngeal carcinoma cells in vitro and in vivo. Acta Histochemica, 125(1), 151978. https:\/\/doi.org\/10.1016\/j.acthis.2022.151978","journal-title":"Acta Histochemica"},{"key":"2342_CR45","doi-asserted-by":"publisher","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","volume":"21","author":"RF Ozols","year":"2003","unstructured":"Ozols, R. F., Bundy, B. N., Greer, B. E., Fowler, J. M., Clarke-Pearson, D., Burger, R. A., Mannel, R. S., DeGeest, K., Hartenbach, E. M., Baergen, R., & Oncology, G., G (2003). Phase III trial of carboplatin and Paclitaxel compared with cisplatin and Paclitaxel in patients with optimally resected stage III ovarian cancer: A gynecologic oncology group study. Journal of Clinical Oncology, 21(17), 3194\u20133200. https:\/\/doi.org\/10.1200\/JCO.2003.02.153","journal-title":"Journal of Clinical Oncology"},{"key":"2342_CR46","doi-asserted-by":"publisher","first-page":"W398","DOI":"10.1093\/nar\/gkae253","volume":"52","author":"Z Pang","year":"2024","unstructured":"Pang, Z., Lu, Y., Zhou, G., Hui, F., Xu, L., Viau, C., Spigelman, A. F., MacDonald, P. E., Wishart, D. S., & Li, S. (2024). MetaboAnalyst 6.0: Towards a unified platform for metabolomics data processing, analysis and interpretation. Nucleic Acids Research, 52(W1), W398\u2013W406. https:\/\/doi.org\/10.1093\/nar\/gkae253","journal-title":"Nucleic Acids Research"},{"key":"2342_CR47","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13048-015-0140-8","volume":"8","author":"LM Poisson","year":"2015","unstructured":"Poisson, L. M., Munkarah, A., Madi, H., Datta, I., Hensley-Alford, S., Tebbe, C., Buekers, T., Giri, S., & Rattan, R. (2015). A metabolomic approach to identifying platinum resistance in ovarian cancer. Journal of Ovarian Research, 8, 13. https:\/\/doi.org\/10.1186\/s13048-015-0140-8","journal-title":"J Ovarian Res"},{"key":"2342_CR48","doi-asserted-by":"publisher","unstructured":"Pokhriyal, R., Hariprasad, R., Kumar, L., & Hariprasad, G. (2019). Chemotherapy resistance in advanced ovarian cancer patients. Biomarkers in Cancer, 11. https:\/\/doi.org\/10.1177\/1179299X19860815","DOI":"10.1177\/1179299X19860815"},{"key":"2342_CR49","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/s41392-023-01399-3","volume":"8","author":"S Qiu","year":"2023","unstructured":"Qiu, S., Cai, Y., Yao, H., Lin, C., Xie, Y., Tang, S., & Zhang, A. (2023). Small molecule metabolites: Discovery of biomarkers and therapeutic targets. Signal Transduction and Targeted Therary, 8, 132. https:\/\/doi.org\/10.1038\/s41392-023-01399-3","journal-title":"Signal Transduct Target Ther"},{"key":"2342_CR50","doi-asserted-by":"publisher","unstructured":"Quintanilla-Casas, B., Bro, R., Hinrich, J. L., & Davie-Martin, C. L. (2023). Tutorial on PARADISe: PARAFAC2-based Deconvolution and Identification System for processing GC\u2013MS data. PROTOCOL (Version 1). https:\/\/doi.org\/10.21203\/rs.3.pex-2143\/v1","DOI":"10.21203\/rs.3.pex-2143\/v1"},{"key":"2342_CR51","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1002\/ijc.2910450306","volume":"45","author":"RJ Schilder","year":"1990","unstructured":"Schilder, R. J., Hall, L., Monks, A., Handel, L. M., Fornace, A. J. Jr., Ozols, R. F., Fojo, A. T., & Hamilton, T. C. (1990). Metallothionein gene expression and resistance to cisplatin in human ovarian cancer. International Journal of Cancer, 45(3), 416\u2013422. https:\/\/doi.org\/10.1002\/ijc.2910450306","journal-title":"International Journal of Cancer"},{"key":"2342_CR52","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.hoc.2011.10.004","volume":"26","author":"JO Schorge","year":"2012","unstructured":"Schorge, J. O., Eisenhauer, E. E., & Chi, D. S. (2012). Current surgical management of ovarian cancer. Hematology Oncology Clinics North America, 26(1), 93\u2013109. https:\/\/doi.org\/10.1016\/j.hoc.2011.10.004","journal-title":"Hematol Oncol Clin North Am"},{"key":"2342_CR53","doi-asserted-by":"publisher","first-page":"tfae044","DOI":"10.1093\/toxres\/tfae044","volume":"13","author":"F Sewell","year":"2024","unstructured":"Sewell, F., Alexander-White, C., Brescia, S., Currie, R. A., Roberts, R., Roper, C., Vickers, C., Westmoreland, C., & Kimber, I. (2024). New approach methodologies (NAMs): Identifying and overcoming hurdles to accelerated adoption. Toxicol Res, 13, tfae044. https:\/\/doi.org\/10.1093\/toxres\/tfae044","journal-title":"Toxicol Res"},{"key":"2342_CR54","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2021). Cancer Statistics, 2021. C Ca: A Cancer Journal for Clinicians, 71, 7\u201333. https:\/\/doi.org\/10.3322\/caac.21654","journal-title":"C Ca: A Cancer Journal for Clinicians"},{"key":"2342_CR55","doi-asserted-by":"publisher","unstructured":"Simic, P., Pljesa, I., Nejkovic, L., Jerotic, D., Coric, V., Stulic, J., Kokosar, N., Popov, D., Savic-Radojevic, A., Pazin, V., & Pljesa-Ercegovac, M. (2022). Glutathione transferase P1: Potential therapeutic target in ovarian cancer. Medicina, 58. https:\/\/doi.org\/10.3390\/medicina58111660","DOI":"10.3390\/medicina58111660"},{"key":"2342_CR56","doi-asserted-by":"publisher","first-page":"116424","DOI":"10.1016\/j.bcp.2024.116424","volume":"227","author":"RB Soares","year":"2024","unstructured":"Soares, R. B., Pinto, J., Amaro, F., Manguinhas, R., Gil, N., Rosell, R., Batinic-Haberle, I., Fernandes, A. S., Oliveira, N. G., Guedes de Pinho, P. (2024). Impact of the redox-active MnTnHex-2-PyP(5+) and cisplatin on the metabolome of non-small cell lung cancer cells. Biochemical Pharmacology, 227, 116424. https:\/\/doi.org\/10.1016\/j.bcp.2024.116424","journal-title":"Biochemical Pharmacology"},{"key":"2342_CR57","doi-asserted-by":"publisher","first-page":"C1071","DOI":"10.1152\/ajpcell.00274.2014","volume":"307","author":"BH Sorensen","year":"2014","unstructured":"Sorensen, B. H., Thorsteinsdottir, U. A., & Lambert, I. H. (2014). Acquired cisplatin resistance in human ovarian A2780 cancer cells correlates with shift in taurine homeostasis and ability to volume regulate. American Journal of Physiology. Cell Physiology, 307(12), C1071\u2013C1080. https:\/\/doi.org\/10.1152\/ajpcell.00274.2014","journal-title":"American Journal of Physiology. Cell Physiology"},{"key":"2342_CR58","doi-asserted-by":"publisher","unstructured":"Sumner, L. W., Amberg, A., Barrett, D., Beale, M. H., Beger, R., Daykin, C. A., Fan, T. W. M., Fiehn, O., Goodacre, R., Griffin, J. L., Hankemeier, T., Hardy, N., Harnly, J., Higashi, R., Kopka, J., Lane, A. N., Lindon, J. C., Marriott, P., Nicholls, A. W., Reily, M. D., Thaden, M. D., & Viant, M. R. (2007). Proposed minimum reporting standards for chemical analysis: Chemical analysis working group (CAWG) metabolomics standards initiative (MSI). Metabolomics, 3, 211\u2013221. https:\/\/doi.org\/10.1007\/s11306-007-0082-2","DOI":"10.1007\/s11306-007-0082-2"},{"key":"2342_CR59","doi-asserted-by":"publisher","unstructured":"Tondo-Steele, K., & McLean, K. (2022). The sweet spot of targeting tumor metabolism in ovarian cancers. Cancers, 14(19), 4696. https:\/\/doi.org\/10.3390\/cancers14194696","DOI":"10.3390\/cancers14194696"},{"key":"2342_CR60","doi-asserted-by":"publisher","first-page":"e0118262","DOI":"10.1371\/journal.pone.0118262","volume":"10","author":"KA Vermeersch","year":"2015","unstructured":"Vermeersch, K. A., Wang, L., Mezencev, R., McDonald, J. F., & Styczynski, M. P. (2015). OVCAR-3 spheroid-derived cells display distinct metabolic profiles. PLoS One, 10(2), e0118262. https:\/\/doi.org\/10.1371\/journal.pone.0118262","journal-title":"PLoS One"},{"key":"2342_CR61","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.cbpa.2017.01.001","volume":"36","author":"MR Viant","year":"2017","unstructured":"Viant, M. R., Kurland, I. J., Jones, M. R., & Dunn, W. B. (2017). How close are we to complete annotation of metabolomes? Current Opinion in Chemical Biology, 36, 64\u201369. https:\/\/doi.org\/10.1016\/j.cbpa.2017.01.001","journal-title":"Current Opinion in Chemical Biology"},{"key":"2342_CR62","doi-asserted-by":"publisher","first-page":"2367129","DOI":"10.1080\/14756366.2024.2367129","volume":"39","author":"D Wang","year":"2024","unstructured":"Wang, D., Duan, J. J., Guo, Y. F., Chen, J. J., Chen, T. Q., Wang, J., & Yu, S. C. (2024). Targeting the glutamine-arginine-proline metabolism axis in cancer. Journal of Enzyme Inhibition and Medicinal Chemistry, 39(1), 2367129. https:\/\/doi.org\/10.1080\/14756366.2024.2367129","journal-title":"Journal of Enzyme Inhibition and Medicinal Chemistry"},{"key":"2342_CR63","doi-asserted-by":"publisher","first-page":"1231460","DOI":"10.3389\/fonc.2023.1231460","volume":"13","author":"J Yan","year":"2023","unstructured":"Yan, J., Xu, F., Zhou, D., Zhang, S., Zhang, B., Meng, Q., & Lv, Q. (2023). Metabolic reprogramming of three major nutrients in platinum-resistant ovarian cancer. Frontiers in Oncology, 13, 1231460. https:\/\/doi.org\/10.3389\/fonc.2023.1231460","journal-title":"Frontiers in Oncology"},{"key":"2342_CR64","doi-asserted-by":"publisher","unstructured":"Yoo, H. C., & Han, J. M. (2022). Amino acid metabolism in cancer drug resistance. Cells, 11(1), 140. https:\/\/doi.org\/10.3390\/cells11010140","DOI":"10.3390\/cells11010140"},{"key":"2342_CR65","doi-asserted-by":"publisher","first-page":"1054233","DOI":"10.3389\/fonc.2022.1054233","volume":"12","author":"Z Zhang","year":"2022","unstructured":"Zhang, Z., Bao, C., Jiang, L., Wang, S., Wang, K., Lu, C., & Fang, H. (2022). When cancer drug resistance Meets metabolomics (bulk, single-cell and\/or spatial): Progress, potential, and perspective. Frontiers in Oncology, 12, 1054233. https:\/\/doi.org\/10.3389\/fonc.2022.1054233","journal-title":"Frontiers in Oncology"}],"container-title":["Metabolomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11306-025-02342-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11306-025-02342-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11306-025-02342-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T11:17:32Z","timestamp":1764415052000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11306-025-02342-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,16]]},"references-count":66,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2342"],"URL":"https:\/\/doi.org\/10.1007\/s11306-025-02342-z","relation":{},"ISSN":["1573-3890"],"issn-type":[{"type":"electronic","value":"1573-3890"}],"subject":[],"published":{"date-parts":[[2025,10,16]]},"assertion":[{"value":"7 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"150"}}